Intraperitoneal Therapy for Ovarian Cancer
74,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Gebundenes Buch

Filling the need for a text devoted to intraperitoneal therapy for ovarian cancer, this volume presents both the fundamental methods for optimal care, and the most up-to-date results of clinical trial phases I, II and III. Topics include patient criteria, drug selection, administration guides, and more.
Intraperitoneal chemotherapy is increasingly being used as first-line treatment for ovarian cancer. Nevertheless, it is difficult for the oncologist to find a definitive text that documents both the fundamental methods required to optimize therapy and the up-to-date results of phase I, II,…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Filling the need for a text devoted to intraperitoneal therapy for ovarian cancer, this volume presents both the fundamental methods for optimal care, and the most up-to-date results of clinical trial phases I, II and III. Topics include patient criteria, drug selection, administration guides, and more.
Intraperitoneal chemotherapy is increasingly being used as first-line treatment for ovarian cancer. Nevertheless, it is difficult for the oncologist to find a definitive text that documents both the fundamental methods required to optimize therapy and the up-to-date results of phase I, II, and III clinical trials. With this in mind, the editors of Intraperitoneal Chemotherapy have assembled a team of highly experienced clinicians and researchers to cover every aspect of the subject. The topics addressed include treatment principles, patient, drug, and catheter selection, administration guidelines, the role of hyperthermia, supportive care requirements, novel drugs, and the most recent results of clinical trials. This book will be an invaluable source of information for both practicing clinical oncologists and oncologists in training.
Autorenporträt
Prof. Alberts is Director of the Arizona Cancer Center in Tucson, AZ. He led a workshop on intraperitoneal chemotherapy in January 2006 at the Gynecologic Oncology Group meeting with 400 oncologists and nurses present. He also published the results of the first ever phase III trial comparing IV to IP chemotherapy in the New England Journal of Medicine.